U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H17ClN6O3
Molecular Weight 388.8089
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESZOPICLONE

SMILES

CN1CCN(CC1)C(=O)O[C@@]2([H])c3c(C(=O)N2c4ccc(cn4)Cl)nccn3

InChI

InChIKey=GBBSUAFBMRNDJC-INIZCTEOSA-N
InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/eszopiclone.html

Eszopiclone is a nonbenzodiazepine hypnotic, pyrrolopyrazine derivative of the cyclopyrrolone class and is indicated for the short-term treatment of insomnia. While Eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Eszopiclone binds selectively to the brain alpha subunit of the GABA A omega-1 receptor. The mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors as an agonist and interacts with GABA-receptor complexes. Used for the treatment of insomnia.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LUNESTA

Approved Use

LUNESTA is indicated for the treatment of insomnia.

Launch Date

1.10298241E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
19.88 ng/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
40.28 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
6.15 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
25.48 ng/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
26.18 ng/mL
3 mg 1 times / day multiple, oral
dose: 3 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
54.68 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
59.63 ng/mL
6 mg 1 times / day multiple, oral
dose: 6 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10.29 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.58 ng/mL
1 mg 1 times / day multiple, oral
dose: 1 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
166.21 ng × h/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
338.26 ng × h/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
54.76 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
187.76 ng × h/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
191.07 ng × h/mL
3 mg 1 times / day multiple, oral
dose: 3 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
379.04 ng × h/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
409.31 ng × h/mL
6 mg 1 times / day multiple, oral
dose: 6 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
62.96 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
66.05 ng × h/mL
1 mg 1 times / day multiple, oral
dose: 1 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.7 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ESZOPICLONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
44.45%
ESZOPICLONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
6 mg single, oral
Highest studied dose
Dose: 6 mg
Route: oral
Route: single
Dose: 6 mg
Sources: Page: p.564
healthy, 25–38
n = 12
Health Status: healthy
Age Group: 25–38
Sex: M+F
Population Size: 12
Sources: Page: p.564
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.564
healthy, 25–40
n = 8
Health Status: healthy
Age Group: 25–40
Sex: M+F
Population Size: 8
Sources: Page: p.564
90 mg single, oral
Overdose
Dose: 90 mg
Route: oral
Route: single
Dose: 90 mg
Sources:
healthy, 86
n = 1
Health Status: healthy
Age Group: 86
Sex: F
Population Size: 1
Sources:
Disc. AE: Coma...
AEs leading to
discontinuation/dose reduction:
Coma
Sources:
270 mg single, oral
Overdose
Dose: 270 mg
Route: oral
Route: single
Dose: 270 mg
Sources: Page: p.13
healthy
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Disc. AE: CNS depression, Alertness decreased...
AEs leading to
discontinuation/dose reduction:
CNS depression
Alertness decreased
Coordination impaired
Anaphylactic reaction (severe)
Anaphylactoid reaction (severe)
Angioedema
Anaphylaxis
Abnormal thinking
Abnormal behaviour NOS
Hallucinations
Abnormal behaviour NOS
Depression worsened
Suicidal ideation
Sources: Page: p.1
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Other AEs: Dysgeusia, Dizziness...
Other AEs:
Dysgeusia (below serious, 8 patients)
Dizziness (below serious, 6 patients)
Somnolence (below serious, 4 patients)
Abdominal pain upper (below serious, 6 patients)
Vomiting (below serious, 10 patients)
Abdominal discomfort (below serious, 4 patients)
Toothache (below serious, 4 patients)
Upper respiratory tract infection (below serious, 13 patients)
Nasopharyngitis (below serious, 9 patients)
Oropharyngeal pain (below serious, 6 patients)
Irritability (below serious, 4 patients)
Nasal congestion (below serious, 1 patient)
Sources:
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 14
Health Status: unhealthy
Condition: Osteoarthritis
Population Size: 14
Sources:
Other AEs: Restlessness...
Other AEs:
Restlessness (below serious, 1 patient)
Sources:
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Other AEs: Fatigue, Drowsiness...
Other AEs:
Fatigue (serious, 1 patient)
Drowsiness (below serious, 8 patients)
Weakness (below serious, 2 patients)
Irritability (below serious, 2 patients)
Headache (below serious, 4 patients)
Nervousness (below serious, 1 patient)
Malaise (below serious, 3 patients)
Delusions (below serious, 1 patient)
Dizziness (below serious, 2 patients)
Vision blurred (below serious, 1 patient)
Nasal congestion (below serious, 2 patients)
Dry mouth (below serious, 5 patients)
Bad taste (below serious, 7 patients)
Tremor (below serious, 1 patient)
Ataxia (below serious, 1 patient)
Nausea and vomiting (below serious, 2 patients)
Abdominal discomfort (below serious, 1 patient)
Diarrhea (below serious, 1 patient)
Sweating (below serious, 1 patient)
Decreased appetite (below serious, 1 patient)
Increased appetite (below serious, 2 patients)
Weight loss (below serious, 2 patients)
Sources:
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Other AEs: Sedation, Respiratory distress...
Other AEs:
Sedation (serious, 1 patient)
Respiratory distress (serious, 1 patient)
Headache (below serious, 22 patients)
Dysgeusia (below serious, 22 patients)
Dizziness (below serious, 13 patients)
Somnolence (below serious, 6 patients)
Abdominal pain upper (below serious, 8 patients)
Vomiting (below serious, 5 patients)
Nausea (below serious, 7 patients)
Abdominal discomfort (below serious, 8 patients)
Toothache (below serious, 2 patients)
Urinary tract infection (below serious, 4 patients)
Pyrexia (below serious, 8 patients)
Nasal congestion (below serious, 4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Coma Disc. AE
90 mg single, oral
Overdose
Dose: 90 mg
Route: oral
Route: single
Dose: 90 mg
Sources:
healthy, 86
n = 1
Health Status: healthy
Age Group: 86
Sex: F
Population Size: 1
Sources:
Abnormal behaviour NOS Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Abnormal behaviour NOS Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Abnormal thinking Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Alertness decreased Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Anaphylaxis Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Angioedema Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
CNS depression Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Coordination impaired Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Depression worsened Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Hallucinations Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Suicidal ideation Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Anaphylactic reaction severe
Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Anaphylactoid reaction severe
Disc. AE
3 mg 1 times / day multiple, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Insomnia
Sources: Page: p.1
Nasal congestion below serious, 1 patient
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Vomiting below serious, 10 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Upper respiratory tract infection below serious, 13 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Abdominal discomfort below serious, 4 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Irritability below serious, 4 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Somnolence below serious, 4 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Toothache below serious, 4 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Abdominal pain upper below serious, 6 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Dizziness below serious, 6 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Oropharyngeal pain below serious, 6 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Dysgeusia below serious, 8 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Nasopharyngitis below serious, 9 patients
2 mg 1 times / day steady, oral (max)
Dose: 2 mg, 1 times / day
Route: oral
Route: steady
Dose: 2 mg, 1 times / day
Sources:
unhealthy
n = 163
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 163
Sources:
Restlessness below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 14
Health Status: unhealthy
Condition: Osteoarthritis
Population Size: 14
Sources:
Abdominal discomfort below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Ataxia below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Decreased appetite below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Delusions below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Diarrhea below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Nervousness below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Sweating below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Tremor below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Vision blurred below serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Dizziness below serious, 2 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Increased appetite below serious, 2 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Irritability below serious, 2 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Nasal congestion below serious, 2 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Nausea and vomiting below serious, 2 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Weakness below serious, 2 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Weight loss below serious, 2 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Malaise below serious, 3 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Headache below serious, 4 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Dry mouth below serious, 5 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Bad taste below serious, 7 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Drowsiness below serious, 8 patients
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Fatigue serious, 1 patient
3 mg 1 times / day steady, oral
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Condition: Schizophrenia
Population Size: 19
Sources:
Dizziness below serious, 13 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Toothache below serious, 2 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Dysgeusia below serious, 22 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Headache below serious, 22 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Nasal congestion below serious, 4 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Urinary tract infection below serious, 4 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Vomiting below serious, 5 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Somnolence below serious, 6 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Nausea below serious, 7 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Abdominal discomfort below serious, 8 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Abdominal pain upper below serious, 8 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Pyrexia below serious, 8 patients
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Respiratory distress serious, 1 patient
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Sedation serious, 1 patient
3 mg 1 times / day steady, oral (max)
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
unhealthy
n = 159
Health Status: unhealthy
Condition: Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Population Size: 159
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
unlikely (co-administration study)
Comment: 5% decrease in AUC when paroxetine was the substrate and esopiclone the interacting drug
Page: 22;147
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
yes
yes (co-administration study)
Comment: Coadministration with ketoconazole resulted in a 2.2-fold increase in exposure to eszopiclone
Page: 22.0
PubMed

PubMed

TitleDatePubMed
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
2007 Feb 15
Prolonged coma after eszopiclone overdose.
2007 Jul
Patents

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Insomnia Initial dose: 1 mg orally immediately before bedtime Maintenance dose: 1 to 3 mg orally immediately before bedtime Maximum dose: 3 mg orally immediately before bedtime
Route of Administration: Oral
10 uM Eszopiclone increased the mean amplitude of the IGV-induced outward current from 19.7 ± 3.9 pA to 47.1 ± 7.8 pA (n = 10) and increased duration from 396.5 ± 24.0 s to 568.8 ± 40.5 s in rat pedunculopontine neurons.
Name Type Language
ESZOPICLONE
HSDB   INN   JAN   MART.   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
ESZOPICLONE [USAN]
Common Name English
1-PIPERAZINECARBOXYLIC ACID, 4-METHYL-, (5S)-6-(5-CHLORO-2-PYRIDINYL)-6,7-DIHYDRO-7-OXO-5H-PYRROLO(3,4-B)PYRAZIN-5-YL ESTER
Common Name English
ESZOPICLONE [JAN]
Common Name English
(+)-(5S)-6-(5-CHLOROPYRIDIN-2-YL)-7-OXO-6,7-DIHYDRO-5H-PYRROLO(3,4-B)PYRAZIN-5-YL 4-METHYLPIPERAZINE-1-CARBOXYLATE
Systematic Name English
ESZOPICLONE [VANDF]
Common Name English
ESZOPICLONE CIV [USP-RS]
Common Name English
LUNESTA
Brand Name English
ESZOPICLONE [MART.]
Common Name English
GSK-1755165
Code English
ZOPICLONE S-FORM [MI]
Common Name English
ESZOPICLONE [USP MONOGRAPH]
Common Name English
ESZOPICLONE [WHO-DD]
Common Name English
ESZOPICLONE [HSDB]
Common Name English
ZOPICLONE S-FORM
MI  
Common Name English
ESZOPICLON
Common Name English
ESZOPICLONE [ORANGE BOOK]
Common Name English
ESZOPICLONE CIV
USP-RS  
Common Name English
ESZOPICLONE [INN]
Common Name English
(S)-ZOPICLONE
Common Name English
ESTORRA
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C29756
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
WHO-VATC QN05CF04
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
WHO-ATC N05CF04
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
LIVERTOX 378
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
Code System Code Type Description
MESH
C515051
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
RXCUI
461016
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C65545
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
LACTMED
Eszopiclone
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
DRUG CENTRAL
1068
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
MERCK INDEX
M11663
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY Merck Index
PUBCHEM
969472
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
IUPHAR
7429
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
CAS
138729-47-2
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
FDA UNII
UZX80K71OE
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
ChEMBL
CHEMBL1522
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
DRUG BANK
DB00402
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
EVMPD
SUB21373
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
INN
8258
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
WIKIPEDIA
ESZOPICLONE
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
HSDB
7472
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY
USP_CATALOG
1255850
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY USP-RS
EPA CompTox
138729-47-2
Created by admin on Sat Jun 26 12:59:00 UTC 2021 , Edited by admin on Sat Jun 26 12:59:00 UTC 2021
PRIMARY